{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-029572","form_type":"8-K","ticker":"GBCS","cik":"0000727346","company_name":"SELECTIS HEALTH, INC.","filed_at":"2025-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.024418+00:00","generated_at":"2026-05-16T12:03:13.439551+00:00","sec_items":["2.03","3.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Selectis Health extends $1.775M notes to Feb 2026, interest rate raised to 13%","bullets":["Maturity extended to Feb 28, 2026 or earlier upon Qualified Transaction; 30-day extensions possible with 0.5% fee.","Interest rate increased from 11% to 13% per annum effective Jan 1, 2026.","Warrants extended to Dec 31, 2027; exercise price unchanged at $2.25 per share.","Kent Lund and Lance Baller appointed to Board of Directors effective Jan 1, 2026.","Solicitation fee of $9,000 paid to GVC Capital LLC in connection with the amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-029572","json":"https://secwatch.observer/filing/0001493152-25-029572.json","markdown":"https://secwatch.observer/filing/0001493152-25-029572.md","text":"https://secwatch.observer/filing/0001493152-25-029572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/727346/000149315225029572/0001493152-25-029572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/727346/000149315225029572/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:03:13.439551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a38225b1d4418dc4f4e22453010948b473ee63fd","claim":"SELECTIS HEALTH, INC. issued convertible note.","evidence_excerpt":"Effective December 31, 2025, the Company entered into a Third Amended and Restated Allonge and Modification Agreement (the “Third Allonge”) with the holders of more than a majority in interest in the Company’s 2018 11% Senior Secured Promissory Notes (the “Notes”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/727346/000149315225029572/0001493152-25-029572-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"convertible note"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}